乳腺癌靶向药物的研究及临床应用新进展

Research and clinical application of targeted drugs for breast cancer

在临床上,乳腺癌属于高发性恶性肿瘤之一,尤其在女性群体中发病率较高,严重损害患者身心健康,甚至威胁生命安全。随科技进步与发展,医疗技术不断提高,尽管已有多种较为有效的化疗药物被广泛应用于乳腺癌治疗中,但对于乳腺癌晚期患者而言,疗效并不理想。近年来,拉帕替尼、曲妥珠单抗等药物的出现,为乳腺癌治疗提供更多选择,并在治疗中取得显著疗效,为乳腺癌分子靶向治疗提供了新思路。随后研发的厄洛替尼、帕妥珠单抗、索拉非尼等靶向药物已逐渐应用于临床治疗中,进一步增强了乳腺癌的治疗效果,为提高患者生存质量,延长生存时间开创了新道路。

In clinic,breast cancer is one of the most frequent malignant tumors,especially in female population.It has a high incidence rate,which seriously damages the physical and mental health of patients and even threatens the safety of life.With the progress and development of science and technology,medical technology continues to improve,although a variety of more effective chemotherapy drugs have been widely used in the treatment of breast cancer,but for patients with advanced breast cancer,the curative effect is not ideal.In recent years,lapatinib,trastuzumab and other drugs have provided more choices for breast cancer treatment,and achieved significant curative effect in the treatment,which provides a new idea for molecular targeted therapy of breast cancer.Subsequently,erlotinib,patuzumab,sorafenib and other targeted drugs have been gradually applied in clinical treatment,further enhancing the therapeutic effect of breast cancer,and creating a new way to improve the quality of life and prolong the survival time of patients.